Immix Biopharma (IMMX) Share-based Compensation (2021 - 2026)
Immix Biopharma (IMMX) posted Share-based Compensation of $508065.0 for Q1 2026, down 79.19% sequentially from $2.4 million in Q4 2025, and up 16.88% YoY from $434701.0 in Q1 2025.
Immix Biopharma (IMMX) Share-based Compensation (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Share-based Compensation for 6 years, with the latest figure at $508065.0 in Q1 2026.
- Quarterly Share-based Compensation rose 16.88% year-over-year to $508065.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 83.59% YoY) and the FY2025 annual result came in at $2.4 million, down 19.16% from the prior year.
- Share-based Compensation slipped to $508065.0 in Q1 2026 per IMMX's latest filing, from $2.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.4 million in Q4 2025 and troughed at $65074.0 in Q1 2022.
- A 5-year average of $552653.4 and a median of $441178.5 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 1432.23% in 2022, then tumbled 74.46% in 2025.
- Over 5 years, Share-based Compensation stood at $130094.0 in 2022, then soared by 707.73% to $1.1 million in 2023, then sank by 32.85% to $705653.0 in 2024, then soared by 246.04% to $2.4 million in 2025, then sank by 79.19% to $508065.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $508065.0, $2.4 million, and $75046.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 910,640.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 910,640.00 |
| Jun 30, 2026 | 910,640.00 |
| Mar 31, 2026 | 508,065.00 |
| Mar 31, 2026 | 508,065.00 |
| Dec 31, 2025 | 2.44 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Jun 30, 2025 | 75,046.00 |
| Jun 30, 2025 | 75,046.00 |
| Mar 31, 2025 | 434,701.00 |
| Mar 31, 2025 | 434,701.00 |
| Dec 31, 2024 | 705,653.00 |
| Dec 31, 2024 | 705,653.00 |
| Sep 30, 2024 | 450,299.00 |
| Sep 30, 2024 | 450,299.00 |
| Jun 30, 2024 | 293,802.00 |
| Jun 30, 2024 | 293,802.00 |
| Mar 31, 2024 | 943,264.00 |
| Mar 31, 2024 | 943,264.00 |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2023 | 1.05 Mn |